Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 264

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Long‐term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three‐month, randomized, placebo‐controlled trial

Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Burmester, G., Golder, W., Gromnica‐Ihle, E., Kellner, H., Schneider, M., Sörensen, H., Zeidler, H., Reddig, J., Sieper, J. · 2003 · Arthritis & Rheumatism

Abstract

Objective: Treatment of ankylosing spondylitis (AS) with infliximab, an anti–tumor necrosis factor α monoclonal antibody, was shown to be efficacious in patients with active disease during a 3‐month treatment period. The purpose of this study was to evaluate the efficacy and safety of infliximab treatment of AS for a 1‐year period. Methods: This study was an open, observational, extension study of a 3‐month, randomized, placebo‐controlled trial. All patients who had tolerated infliximab (infliximab/infliximab group) or placebo (placebo/infliximab 12‐week crossover group) therapy for 3 months entered the open extension trial (n = 65). Infliximab was administered at a dosage of 5 mg/kg every 6 weeks after the induction phase (weeks 0, 2, and 6). The primary end point was a 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Results: At week 54, a total of 54 of the 69 patients (78%) continued to take infliximab. The intent‐to‐treat primary efficacy analysis at week 54 showed that 47% of patients in the infliximab/infliximab group (95% confidence interval 31–63) and 51% of the patients in the placebo/infliximab group (95% confidence interval 36–67) achieved 50% improvement in BASDAI scores. In the analysis of those who completed the study, the mean BASDAI scores improved between weeks 0 and 54 in both treatment groups: from 6.6 to 2.4 in the infliximab/infliximab group and from 6.3 to 2.6 in the placebo/infliximab group. The dosage of nonsteroidal antiinflammatory drugs was reduced in ∼70% of the patients. There were significant improvements in measures of functioning, metrologic parameters, and quality of life. Between weeks 12 and 54, a total of 4 patients had serious adverse events that were possibly related to infliximab and resulted in their discontinuing the study. Conclusion: Infliximab therapy in AS patients resulted in a rapid and significant improvement in BASDAI scores (>50% improvement) and a durable response for 1 year. The safety profile of infliximab in AS was comparable to that observed in the postmarketing experience for the approved indications.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.11104

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 264

Metadata

Authors
Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Burmester, G., Golder, W., Gromnica‐Ihle, E., Kellner, H., Schneider, M., Sörensen, H., Zeidler, H., Reddig, J., & Sieper, J.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
2003-08
Volume
48
Issue
8
Pages
2224-2233
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
OpenAlex
W2034608764
Cited by
264
References
26
FWCI
19.94
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long‐term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three‐month, randomized, placebo‐controlled trial. https://app.cochat.ai/papers/10.1002/art.11104
The paper
Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Burmester, G., Golder, W., Gromnica‐Ihle, E., Kellner, H., Schneider, M., Sörensen, H., Zeidler, H., Reddig, J., & Sieper, J. (2003). Long‐term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three‐month, randomized, placebo‐controlled trial. Arthritis & Rheumatism. https://doi.org/10.1002/art.11104

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.